News
09-22-2010, 08:10 AM
Celsion Corporation (Nasdaq: CLSN) announced today that an abstract on its Phase I/II DIGNITY trial of ThermoDox® in Recurrent Chest Wall (RCW) Breast Cancer has been accepted for a poster session at the 2010 Breast Cancer Symposium...
More... (http://mnt.to/f/3K93)
More... (http://mnt.to/f/3K93)